Leer-Salvesen Sunniva, Dybvik Eva, Dahl Ola E, Gjertsen Jan-Erik, EngesæTer Lars B
b Department of Clinical Medicine , University of Bergen , Bergen.
a The Norwegian Arthroplasty Register, Department of Orthopaedic Surgery , Haukeland University Hospital , Bergen.
Acta Orthop. 2017 Feb;88(1):48-54. doi: 10.1080/17453674.2016.1235427. Epub 2016 Sep 23.
Background and purpose - Controversies exist regarding thromboprophylaxis in orthopedic surgery. Using data in the nationwide Norwegian Hip Fracture Register (NHFR) with postoperative death and reoperation in the first 6 months after surgery as endpoints in the analyses, we determined whether the thromboprophylaxis in patients who undergo hemiarthroplasty for femoral neck fracture should start preoperatively or postoperatively. Patients and methods - After each operation for hip fracture in Norway, the surgeon reports information on the patient, the fracture, and the operation to the NHFR. Cox regression analyses were performed with adjustments for age, ASA score, gender, type of implant, length of surgery, and year of surgery. Results - During the period 2005-2014, 25,019 hemiarthroplasties as treatment for femoral neck fractures were reported to the registry. Antithrombotic medication was given to 99% of the patients. Low-molecular-weight heparin predominated with dalteparin in 57% of the operations and enoxaparin in 41%. Only operations with these 2 drugs and with known information on preoperative or postoperative start of the prophylaxis were included in the analyses (n = 20,241). Compared to preoperative start of thromboprophylaxis, postoperative start of thromboprophylaxis gave a higher risk of death (risk ratio (RR) = 1.13, 95% CI: 1.06-1.21; p < 0.001) and a higher risk of reoperation for any reason (RR =1.19, 95% CI: 1.01-1.40; p = 0.04), whereas we found no effect on reported intraoperative bleeding complication or on the risk of postoperative reoperation due to hematoma. The results did not depend on whether the initial dose of prophylaxis was the full dosage or half of the standard dosage. Interpretation - Postoperative start of thromboprophylaxis increased the mortality and risk of reoperation compared to preoperative start in femoral neck fracture patients operated with hemiprosthesis. The risks of bleeding and of reoperation due to hematoma were similar in patients who received low-molecular-weight heparin preoperatively and in those who received it postoperatively.
背景与目的——骨科手术中的血栓预防存在争议。利用挪威全国髋部骨折登记处(NHFR)的数据,将术后死亡和术后6个月内再次手术作为分析终点,我们确定了接受股骨颈骨折半关节置换术的患者的血栓预防应在术前还是术后开始。患者与方法——在挪威每次髋部骨折手术后,外科医生会向NHFR报告有关患者、骨折和手术的信息。进行Cox回归分析,并对年龄、美国麻醉医师协会(ASA)评分、性别、植入物类型、手术时长和手术年份进行校正。结果——在2005年至2014年期间,登记处共收到25,019例作为股骨颈骨折治疗方式的半关节置换术报告。99%的患者接受了抗血栓药物治疗。低分子量肝素占主导,其中达肝素在57%的手术中使用,依诺肝素在41%的手术中使用。分析仅纳入使用这两种药物且有预防措施术前或术后开始的已知信息的手术(n = 20,241)。与术前开始血栓预防相比,术后开始血栓预防的患者死亡风险更高(风险比(RR)= 1.13,95%置信区间:1.06 - 1.21;p < 0.001),因任何原因再次手术的风险也更高(RR = 1.19,95%置信区间:1.01 - 1.40;p = 0.04),而我们发现对报告的术中出血并发症或因血肿导致的术后再次手术风险没有影响。结果不取决于预防的初始剂量是全剂量还是标准剂量的一半。解读——与术前开始相比,接受半关节置换术的股骨颈骨折患者术后开始血栓预防会增加死亡率和再次手术风险。术前和术后接受低分子量肝素治疗的患者出血风险和因血肿再次手术的风险相似。